Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 24, 2024 7:01pm

101 Views

Post# 36056777

RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

October 2023 -

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

Quote: "TILs encompass a range of lymphocytes, including B cells, T cells, and plasma cells, contributing to the intricate immune modulation in the TME [42,43,44]. TILs can be further categorized into various cell types, including CD8+ cytotoxic T lymphocytes, CD8+ tissue-resident memory T (TRM) cells, natural killer (NK) cells, CD4+ T helper 1/2/17 (Th1, Th2, and Th17) cells, CD4+ regulatory T cells (Tregs), CD4+ follicular helper (Tfh) T cells, and tumor-infiltrating B cells (Table 2) [42]. Their composition can change during BC progression and treatment. "

" Oncolytic viruses (OVs) and CVs constitute a cutting-edge and promising treatment strategy. The foundation of CVs treatment is the immune system’s capacity to distinguish between antigens produced improperly in tumor cells and those found on the surface of healthy cells [34,214].

Regarding Ovs, this approach is predicated on inducing systemic anti-tumor immunity while selectively infecting and killing tumor cells with little to no impact on healthy tissue [213,215]. By boosting immune cell infiltration and promoting subsequent cascade immunological networks, Ovs can be genetically modified to express immune cytokines and enhance immune responses. Therapy with Ovs is now a growing area of research."

"Although immunotherapy is a promising strategy for treating cancer, it can be difficult to manage immune responses because of the many cellular and molecular connections within the immune system. Combination immunotherapy is considered a potential approach for BC immunotherapy since concentrating on only one aspect of the immune system is insufficient [205]. Furthermore, the simultaneous targeting of multiple immune Checkpoint Inhibitors (CIs) and the incorporation of OVs and CVs hold the potential to overcome resistance and improve treatment responses [207]. Finding new predictive biomarkers of response to immune CIs and combination therapies is crucial to help with patient classification and therapeutic decision-making."

https://www.mdpi.com/1422-0067/24/20/15332

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects